62 results about "Incretin" patented technology

Disclosed are methods of improving treatment adherence and compliance after discontinuation of incretin-based therapies, such as GLP-1 and / or GIP agonists, using pharmacotherapies comprising the disclosed therapeutic compounds and combinations. In some aspects, methods include treatment of psychological factors affecting other medical conditions (PFAOMC) following the administration of incretin-based therapies to treat obesity or hyperglycemia, and related disorders. In some aspects, disclosed pharmacotherapies for use in the methods include agents that modulate monoaminergic neurotransmission, administered alone or together, such as in disclosed combinations having advantageous synergistic effects.

Incretin analogs are provided that have activity at each of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as type 2 diabetes mellitus, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and obesity.

The invention features methods of treating a subject who is undergoing treatment with or previously underwent treatment with an incretin-based therapy by administering a polypeptide including an activin receptor type II (ActRII) chimera. The extracellular ActRII chimera may be fused to an Fc domain monomer. The incretin-based therapy may be, e.g., a GLP-1 receptor agonist or a DPP-4 inhibitor.

Incretin analogs and their use. It contains a triple-acting agent protein for human glucose-dependent insulinotropic polypeptide (GIP) receptor, glucagon-like peptide-1 (GLP-1) receptor and glucagon (GCG) receptor, and is useful for the treatment of type 2 diabetes (T2D), obesity, non-alcoholic fatty liver disease (NAFLD) and other carbohydrate and lipid metabolism disorders.

The present disclosure relates to a method of preventing or treating a disease or disorder in a subject in need thereof, wherein administration of a composition of the present disclosure is effective to result in an increase of energy expenditure in the subject. The present disclosure provides a method of reducing fat mass and / or improving glycemic control in a subject in need thereof. The present disclosure provides a method of promoting weight loss and weight maintenance. The present disclosure provides a method of maintaining lean mass. Compositions for use in the methods include a compound of formula (I), (II), or (III), or pharmaceutically acceptable salts thereof, or in combination with a compound selected from the group consisting of an ACC2 inhibitor and an incretin mimetic.

A computer implemented method for determining a dosage of semaglutide for administering to a patient for the treatment of obesity includes receiving patient data relating to a patient, wherein the patient data includes patient weight data; processing the patient data with a dosage calculator to determine the dosage of semaglutide for administering to the patient; and administering the dosage.

Provided herein are incretin analog compounds that are GLP-1 / GIP / Gcg receptor triple agonists and their medical use in the treatment and / or prevention of a disease such as dyslipidemia, fatty liver disease, metabolic syndrome, MASH, MAFLD, obesity and T2DM.

Doses and dosing regimens for incretin analogs are disclosed comprising determining and administering doses of long-acting incretin analogs suitable for once-weekly dosing, such as a glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) (GGG) tri-receptor agonist.

The present invention provides a method for treating obesity or an obesity-related disease or disorder, comprising administering a PYY analog in combination with an incretin, wherein the patient's insulin sensitivity is improved with treatment.

The invention discloses preparation and application of a corn polypeptide with functions of inhibiting amyloglucosidase activity and promoting GLP-1 secretion, and belongs to the technical field of functional food. And the corn polypeptide is PYPR, PPAPR and PLRP (Poly Lactic Polymerase Chain Reaction). The corn polypeptide is obtained by enzymolysis of corn protein through alkaline protease, and is novel in structure and easy to prepare. The corn polypeptide can inhibit the activity of amyloglucosidase in vitro, can significantly promote GLP-1 secretion, and can up-regulate the expression of gcg and gc3 genes related to GLP-1 synthesis and a polypeptide recognition receptor GPR93 by regulating Ca < 2 + > influx and an ATP signal channel, thereby improving the steady state of blood glucose. The invention provides reference for developing functional food or health care products with the functions of reducing blood sugar and promoting secretion of insulin.

Orally administered pharmaceutical compositions comprising incretin or its analogues or derivatives are presented, which allow for prolonged glycemic control. The formulations presented herein incorporate a self-emulsifying drug delivery system (SEDDS). Advantageously, such formulations provide protection in the upper gastrointestinal tract from proteolytic conditions while allowing for efficient drug release and absorption in the lower gastrointestinal tract.

Doses and dosing regimens for incretin analogs are disclosed comprising determining and administering doses of long-acting incretin analogs suitable for once-weekly dosing, such as a glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) (GGG) tri-receptor agonist.

The invention provides an insulinotropic polypeptide analogue and application thereof, and relates to the technical field of polypeptide preparation and application thereof. The intestinal insulinotropic polypeptide analogue comprises a co-agonist, the co-agonist is GLP-1, GIP and GCG three-receptor co-agonist polypeptide which is in acylation connection with a fatty acid side chain, and the amino acid sequence of the polypeptide or a salt thereof or a solvate thereof is shown as the following formula: Y (Aib) QGTFTSDX10SIX13LDX16X17AQ (Aib) X21FIX24X25LX27EGGPSSGAPPPS-NH2. In the present invention, it provides an enteric insulinotropic analogue having activity in each of a glucose-dependent insulinotropic polypeptide, a glucagon-like peptide-1, and a glucagon receptor, the polypeptide analogue can be used for treating and preventing metabolic disorders and other diseases including diabetes mellitus, obesity, metabolic syndromes and related diseases through various administration modes, and the polypeptide analogue can be used for treating and preventing metabolic disorders including diabetes mellitus, obesity, metabolic syndromes and related diseases through various administration modes.

To provide apparatuses and methods for stimulating L cells of the small intestine to produce incretins and other peptides for treatment of various diseases and conditions including diabetes and obesity.SOLUTION: Embodiments of the invention provide apparatuses and methods for stimulating L cells in the intestinal tract to produce incretins for treatment of conditions including diabetes and obesity. Many embodiments provide a method and apparatus for treatment of diabetes by electrically stimulating L cells for secretion of incretins, so as to stimulate or otherwise modulate production of insulin. Particular embodiments provide a swallowable capsule for stimulating L cells in the intestinal tract as the capsule moves through the tract.SELECTED DRAWING: Figure 4

Disclosed are compounds that are parathyroid hormone receptor 1 agonists, and methods useful for preventing or treating osteoporosis, fracture, osteomalacia, arthritis, thrombocytopenia, hypoparathyroidism, hyperphosphatemia or tumoral calcinosis. Also disclosed are agonists of GLP-1R, GCGR, and / or GIPR, and methods of treating various therapeutic indications by administering an effective amount of an agonist of GLP-1R, GCGR, and / or GIPR.

The present invention provides methods and compositions for preventing, reducing, or treating adverse effects caused by an incretin agonist or antagonist containing weight loss drug or a sodium-glucose transport protein 2 (SGLT-2) inhibitor in a subject who is under treatment with the incretin agonist or antagonist containing weight loss drug or SGLT-2 inhibitor. The method comprises coadministering or administering after discontinuation of the incretin agonist or antagonist containing weight loss drug or SGLT-2 inhibitor to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound represented by a structure of Formulas I, II, VIII, IX, X, XI, XII, XIII, and XIV disclosed herein to the subject under incretin agonist or antagonist containing drug or SGLT-2 agent therapy.

Disclosed are compounds that are parathyroid hormone receptor 1 agonists, and methods useful for preventing or treating osteoporosis, fracture, osteomalacia, arthritis, thrombocytopenia, hypoparathyroidism, hyperphosphatemia or tumoral calcinosis. Also disclosed are agonists of GLP-1R, GCGR, and / or GIPR, and methods of treating various therapeutic indications by administering an effective amount of an agonist of GLP-1R, GCGR, and / or GIPR.

The present invention provides methods and compositions for preventing, reducing, or treating adverse effects caused by an incretin agonist or antagonist containing weight loss drug or a sodium-glucose transport protein 2 (SGLT-2) inhibitor in a subject who is under treatment or stops treatment with the incretin agonist or antagonist containing weight loss drug or SGLT-2 inhibitor. The method comprises co-administering or administering after discontinuation of the incretin agonist or antagonist containing weight loss drug or SGLT-2 inhibitor to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound represented by a structure of Formulas I, II, VIII, IX, X, XI, XII, XIII, and XIV disclosed herein to the subject under incretin agonist or antagonist containing drug or SGLT-2 agent therapy.

The invention relates to construction and an application technology of blood-glucose-reducing and thrombus-resisting lactic acid bacteria (HAL). 5 copies of long-acting insulin enterotropin (rolGLP-1) are respectively and seamlessly connected and fused with nattokinase (NK) and hirudin (HV) in series to obtain the blood-glucose-reducing antithrombotic peptide gene (HAP), and the product has dual functions of preventing and treating diabetes and thrombus complications thereof. A food-grade lactic acid bacteria HAP secretory expression vector pMG36-LacZ-Usp45-5rolGLP-1-NK (and-HV) is created by using beta galactosidase selection markers, and MG1363 competent cells are transformed by using the food-grade lactic acid bacteria HAP secretory expression vector so as to obtain lactic acid bacteria HAL1 (secretory expression insulinotropin-nattokinase) and HAL-2 (secretory expression insulinotropin-hirudin) which are stable in heredity and efficiently secrete HAP. Through intragastric administration of HAL samples to mouse thrombus and diabetes models, it is proved that HAL has good blood glucose reducing and thrombus resisting effects. The invention can be used for developing difunctional dietary therapy type blood glucose-reducing and thrombus-resisting lactic acid bacteria health-care products and beverages for simultaneously treating diabetes and thrombus complications thereof.

It relates to incretin analog compounds that are GLP-1 / GIP / GCG receptor triple agonists and their medical use in the treatment and / or prevention of a disease such as dyslipidemia, fatty liver disease, metabolic syndrome, MASH, obesity and T2DM.

The present invention relates to the field of treatment for body composition changes in weight management. In some embodiments, the present invention provides compositions and methods for mitigating the adverse effects of treatment by weight loss drugs that suppress appetite including incretin agonist or antagonist containing drugs such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) or by sodium-glucose transport protein 2 (SGLT-2) inhibitors.

Doses and dosing regimens for incretin analogs are disclosed comprising determining and administering doses of long-acting incretin analogs suitable for once-weekly dosing, such as a glucagon-like peptide-1 (GLP-1) and glucagon (Gcg) co-agonist.

Methods of treating metabolic disorders are disclosed herein, wherein the methods administer combinations of a sodium / glucose co- transporter 1 (SGLT1) inhibitor with a glucagon-like peptide agonist 1 (GLP 1), a gastric inhibitory peptide- 1 (GIP-1) analog, and / or d) a dual GLP-1-GIP-l receptor agonist.

Disclosed herein are methods of treating metabolic disorders, wherein the method administers a combination of a sodium / glucose co-transporter 1 (SGLT1) inhibitor and a glucagon-like peptide agonist 1 (GLP 1), a Gastrosuppressive Peptide-1 (GIP-1) analog, and / or d) a dual GLP-1-GIP-1 receptor agonist.

The present disclosure relates to isolated oligopeptides capable of activating glucagon-like peptide (GLP) receptors, as well as formulations of the oligopeptides. The formulations are suitable for improving glycemic control and reducing excess body weight of overweight individuals.

A computer implemented method for determining a dosage of Cagrisema for administering to a patient for the treatment of obesity, the method comprising: receiving patient data relating to a patient, wherein the patient data includes patient weight data; processing the patient data including the patient weight data with a dosage calculator to determine the dosage of Cagrisema for administering to the patient wherein the dosage calculator is derived from a pharmacokinetic, PK, model; and indicating the dosage.

Compositions are provided that include an incretin analog having activity at each of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG) receptors (i.e., avian receptor agonists) and one or more additional agents, such as a tonicity agent and a preservative. Methods are also provided for treating diseases, such as type 2 diabetes, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and obesity, with the compositions.

Incretin analogs are provided that have activity at each of the GIP, GLP-1 and glucagon receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as diabetes mellitus, dyslipidemia, fatty liver disease, metabolic syndrome, non-alcoholic steatohepatitis and obesity.

To provide a medicine that can be used for treating diabetes mellitus, obesity, NASH and / or dyslipidemia.SOLUTION: A medicine contains a compound including a specific sequence or pharmaceutically acceptable salt thereof, which is used simultaneously or continuously and in combination separately from incretin or incretin analog for treating type 2 diabetes mellitus, obesity, dyslipidemia or NASH. The incretin or incretin analog is selected from the group consisting of GIP / GLP-1 dual agonist, glucagon, GIP, and triagonist of GLP-1, analog of oxyntomodulin, and GLP-1 agonist of oxyntomodulin.SELECTED DRAWING: None

Embodiments of the invention provide shaped masses comprising one or more drugs such as proteins or polypeptides and methods for forming such shaped masses. One embodiment provides a shaped mass comprising a drug such as a protein or polypeptide having a biological activity in the body of a mammal. The shaped mass is formed by compression of a precursor material comprising the drug wherein an amount of biologically active drug in the mass is a preserved above a minimum level. Drugs which may be incorporated into the shaped mass may include one or more glucose regulating proteins such as insulin, incretins; and immunoglobulins such as TNF-inhibiting antibodies or interleukin neutralizing antibodies. Embodiments of the shaped mass may be incorporated into a tissue penetrating member which is inserted into the intestinal wall allowing for the oral delivery of proteins and peptides which would otherwise be degraded in the intestinal tract.